Detection of the Fingerprint of the Electrophysiological Abnormalities that Increase Vulnerability to Life-Threatening Ventricular Arrhythmias

Reduction of sudden death requires accurate identification of patients at risk for ventricular tachycardia (VT) and effective therapies. The Multicenter Unsustained Tachycardia Trial and Multicenter Automatic Defibrillator Implantation Trials demonstrate that the implantable cardioverter defibrillator impacts favorably on the incidence of VT in patients with myocardial infarction, underscoring the need to detect the electrophysiologic abnormalities required for the development of VT. Methods used for this purpose include: Holter monitoring, ejection fraction, signal-averaged ECG, heart rate variability, T-wave alternans, baroreflex sensitivity, and programmed stimulation. Performance of each method alone has demonstrated high-negative but low-positive predictive values. Recent studies confirm that their use in combination augments performance.